812 related articles for article (PubMed ID: 18304903)
1. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
2. A strategic framework for novel drug development in multiple myeloma.
Anderson KC; Hannah AL; Pazdur R; Farrell AT
Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
[No Abstract] [Full Text] [Related]
3. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
4. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
5. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
6. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials.
Farrington P; Miller E
Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
[No Abstract] [Full Text] [Related]
8. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
9. [Phase I cancer trials methodology].
Le Tourneau C; Faivre S; Raymond E; Diéras V
Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
[TBL] [Abstract][Full Text] [Related]
10. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
12. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
14. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
15. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
16. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
17. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
18. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
19. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
20. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
